Disclosure of payments made to HCPs in New Zealand

Partnership among pharmaceutical companies, regulators, Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and patients, is essential for providing access to healthcare. These relationships have helped deliver numerous innovative medicines and changed the way many diseases impact our lives. HCPs have always been and will remain immensely valuable partners for GSK in the way we deliver medicines of value to patients who can benefit.

We are committed to putting the patient at the centre of every decision we take and working with HCPs with the highest level of transparency and ethical standards. We acknowledge the importance of increased transparency around our engagement with HCPs, including transfers of value.

As part of our continued commitment to transparency, we are proactively disclosing all GSK payments made at an individual level to HCPs on an annual basis from 2019 activities onwards.

Our payments to HCPs include the provision of services such as speaking at meetings; attending or supporting educational meetings; providing advice as a member of an Advisory Board or as a consultant; attending academic meetings and conferences; as well as travel and accommodation expenses associated with those services. To view the payments we have made to HCPs in New Zealand, please click on the link below.

1 January 2019 – 31 December 2019



  1. Once published, data will be available online on a three-year rolling basis commencing from 2020 for 2019 activities
  2. All payments are disclosed in NZD based on conversion at the GSK exchange rates prevailing for the month the transaction was recorded
  3. If you are an HCP and have queries about the information disclosed, please direct your query to TOV_HCPNZ@gsk.com